Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions

(2011) Peter Valent et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

(2011) A. R. Ibrahim et al.   HAEMATOLOGICA

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Arsenic trioxide — An old drug rediscovered

(2010) Ashkan Emadi et al.   BLOOD REVIEWS

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

(2010) D Bixby et al.   LEUKEMIA

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Effects of nilotinib on regulatory T cells: the dose matters

(2010) Fei Fei et al.   Molecular Cancer

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arsenic-Induced Carcinogenesis—Oxidative Stress as a Possible Mode of Action and Future Research Needs for More Biologically Based Risk Assessment

(2009) Kirk T. Kitchin et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

(2009) Li Zhou et al.   CLINICAL THERAPEUTICS

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

(2009) Q.-Y. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of intracellular calcium and S-glutathionylation in cell death induced by a mixture of isothiazolinones in HL60 cells

(2008) Simona Frosali et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

(2008) J. Wu et al.   BLOOD

Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH

(2008) Yong Hwan Han et al.   CANCER LETTERS

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Arsenic trioxide mechanisms of action – looking beyond acute promyelocytic leukemia

(2008) Dennis A. Carney   LEUKEMIA & LYMPHOMA

Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone

(2008) P. Kumar et al.   MOLECULAR CANCER THERAPEUTICS